Biomarker Strategic Planning and Literature Review

We announced our new literature-focused features in our last blog post. One of the unique features of our approach is that we use deep learning concepts, a subset of machine learning, to text mine literature. A characteristic of deep learning is that various...

New Pre-clinical Biomarker Coverage

We are excited to announce improvements to BiomarkerBase, increasing the coverage and analysis of literature. We’ve added biomarkers sourced only from literature, representing biomarkers in an earlier stage of development.  With this addition there are two main...

Mary Meeker and Amplion Analysis

When building a company, especially a startup, you look forward to moments that change your trajectory. So, when Mary Meeker included our analysis in her annual Internet trends presentation, it got us thinking. For those of you that don’t know, Mary Meeker is a...

Fail Early, Fail Fast – And Increase Likelihood-of-Approval

What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how...

Top Blog Posts of 2016

As we ramp for a great 2017 we are looking back on what we did in 2016. As we ramp for a great 2017 we are looking back on what we did in 2016. In that spirit, here are the top 5 blog posts of 2016 by views. FDA Introduces a New Test Concept: “Complementary...